The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients.
Products, services, technology
We have four phase 3 products: daridorexant (insomnia), clazosentan (treatment of vasospasm following a sub-arachnoid subarachnoid hemorrhage), aprocitentan (difficult to treat hypertension) and lucerastat (Fabry's disease). Our pipeline has 12 assets in total.